91 related articles for article (PubMed ID: 6839561)
1. Diuretic effect and pharmacokinetics of tizolemide in subjects with normal and decreased renal function.
Beermann B; Odlind B; Wibell L
Clin Nephrol; 1983 Mar; 19(3):124-31. PubMed ID: 6839561
[TBL] [Abstract][Full Text] [Related]
2. Effects of cardiac failure on the pharmacokinetics of the diuretic tizolemide.
Beermann B; Edelstam C
Eur Heart J; 1984 Apr; 5(4):338-42. PubMed ID: 6734643
[TBL] [Abstract][Full Text] [Related]
3. [Mechanism of action of xipamide and its classification as a "low ceiling diuretic". Pharmacodynamic-pharmacokinetic studies in healthy volunteers and in kidney and liver patients].
Knauf H; Mutschler E
Arzneimittelforschung; 2005; 55(1):1-14. PubMed ID: 15727159
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke.
Strid S; Borgå O; Edenius C; Jostell KG; Odergren T; Weil A
Eur J Clin Pharmacol; 2002 Sep; 58(6):409-15. PubMed ID: 12242600
[TBL] [Abstract][Full Text] [Related]
5. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
[TBL] [Abstract][Full Text] [Related]
6. Mathematical evaluation of the effects of tizolemide, furosemide and placebo in healthy adults.
Leary WP; Reyes AJ
S Afr Med J; 1982 Mar; 61(11):398-401. PubMed ID: 7064012
[TBL] [Abstract][Full Text] [Related]
7. The influence of renal function on plasma levels and urinary excretion of acebutolol and its main N-acetyl metabolite.
Kirch W; Köhler H; Berggren G; Braun W
Clin Nephrol; 1982 Aug; 18(2):88-94. PubMed ID: 7140021
[TBL] [Abstract][Full Text] [Related]
8. [Effect of the diuretic Etozolin in patients with normal and impaired renal function (author's transl)].
Scheitza E
Arzneimittelforschung; 1977; 27(9a):1807-14. PubMed ID: 578771
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of incadronate, a new bisphosphonate, in healthy volunteers and patients with malignancy-associated hypercalcemia.
Usui T; Oiso Y; Tomita A; Ogata E; Uchida T; Ikeda K; Watanabe T; Higuchi S
Int J Clin Pharmacol Ther; 1997 Jun; 35(6):239-44. PubMed ID: 9208339
[TBL] [Abstract][Full Text] [Related]
10. [Clinical comparative trial of piretanide and furosemide in patients with advanced renal insufficiency. Drug levels and diuretic potency of single oral doses].
Heuer LJ; Machnik H; Studt J; Fink R
Arzneimittelforschung; 1983; 33(9):1318-21. PubMed ID: 6685516
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of fleroxacin in renal impairment.
Weidekamm E
Am J Med; 1993 Mar; 94(3A):70S-74S. PubMed ID: 8452185
[TBL] [Abstract][Full Text] [Related]
12. Comparison of bioavailability and pharmacokinetics of cimetidine in subjects with normal and impaired renal function.
Guay DR; Matzke GR; Bockbrader HN; Dancik J
Clin Pharm; 1983; 2(2):157-62. PubMed ID: 6883944
[TBL] [Abstract][Full Text] [Related]
13. The pharmacology of cefamandole in patients with reduced renal function.
Czerwinski AW; Pederson JA
Scand J Infect Dis Suppl; 1980; suppl 25():45-8. PubMed ID: 6937951
[TBL] [Abstract][Full Text] [Related]
14. The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment.
Dittrich HC; Gupta DK; Hack TC; Dowling T; Callahan J; Thomson S
J Card Fail; 2007 Oct; 13(8):609-17. PubMed ID: 17923351
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
Smith WB; Dowell JA; Pratt RD
Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
[TBL] [Abstract][Full Text] [Related]
16. Effects of dopamine on renal haemodynamics tubular function and sodium excretion in normal humans.
Olsen NV
Dan Med Bull; 1998 Jun; 45(3):282-97. PubMed ID: 9675540
[TBL] [Abstract][Full Text] [Related]
17. Independent of etozolin elimination of kidney function. Single dose experiments in patients with renal insufficiency.
Knauf H; Hasenfuss G; Wais U; Schollmeyer P; Mutschler E
Arzneimittelforschung; 1980; 30(10):1791-3. PubMed ID: 7192116
[TBL] [Abstract][Full Text] [Related]
18. Study of the elimination kinetics of torasemide, a novel loop diuretic, in renal insufficiency.
Dodion L; Willems JL
Eur J Clin Pharmacol; 1986; 31 Suppl():49-51. PubMed ID: 3780839
[TBL] [Abstract][Full Text] [Related]
19. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
Perucca E; Cloyd J; Critchley D; Fuseau E
Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
